These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26331669)

  • 1. Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.
    Rashad AA; Kalyana Sundaram RV; Aneja R; Duffy C; Chaiken I
    J Med Chem; 2015 Sep; 58(18):7603-8. PubMed ID: 26331669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.
    Zhang S; Holmes AP; Dick A; Rashad AA; Enríquez Rodríguez L; Canziani GA; Root MJ; Chaiken IM
    Retrovirology; 2021 Oct; 18(1):31. PubMed ID: 34627310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.
    Rosemary Bastian A; Nangarlia A; Bailey LD; Holmes A; Kalyana Sundaram RV; Ang C; Moreira DR; Freedman K; Duffy C; Contarino M; Abrams C; Root M; Chaiken I
    J Biol Chem; 2015 Jan; 290(1):529-43. PubMed ID: 25371202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.
    Rashad AA; Acharya K; Haftl A; Aneja R; Dick A; Holmes AP; Chaiken I
    Org Biomol Chem; 2017 Sep; 15(37):7770-7782. PubMed ID: 28770939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.
    Gopi H; Umashankara M; Pirrone V; LaLonde J; Madani N; Tuzer F; Baxter S; Zentner I; Cocklin S; Jawanda N; Miller SR; Schön A; Klein JC; Freire E; Krebs FC; Smith AB; Sodroski J; Chaiken I
    J Med Chem; 2008 May; 51(9):2638-47. PubMed ID: 18402432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes.
    Aneja R; Grigoletto A; Nangarlia A; Rashad AA; Wrenn S; Jacobson JM; Pasut G; Chaiken I
    J Pept Sci; 2019 Apr; 25(4):e3155. PubMed ID: 30809901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide triazole inactivators of HIV-1: how do they work and what is their potential?
    Chaiken I; Rashad AA
    Future Med Chem; 2015; 7(17):2305-10. PubMed ID: 26599515
    [No Abstract]   [Full Text] [Related]  

  • 8. Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.
    Acharya K; Rashad AA; Moraca F; Klasse PJ; Moore JP; Abrams C; Chaiken I
    Proteins; 2017 May; 85(5):843-851. PubMed ID: 28056499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.
    Gopi H; Cocklin S; Pirrone V; McFadden K; Tuzer F; Zentner I; Ajith S; Baxter S; Jawanda N; Krebs FC; Chaiken IM
    J Mol Recognit; 2009; 22(2):169-74. PubMed ID: 18498083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-natural peptide triazole antagonists of HIV-1 envelope gp120.
    Kamanna K; Aneja R; Duffy C; Kubinski P; Rodrigo Moreira D; Bailey LD; McFadden K; Schön A; Holmes A; Tuzer F; Contarino M; Freire E; Chaiken IM
    ChemMedChem; 2013 Feb; 8(2):322-8. PubMed ID: 23239505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.
    Umashankara M; McFadden K; Zentner I; Schön A; Rajagopal S; Tuzer F; Kuriakose SA; Contarino M; Lalonde J; Freire E; Chaiken I
    ChemMedChem; 2010 Nov; 5(11):1871-9. PubMed ID: 20677318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.
    Emileh A; Tuzer F; Yeh H; Umashankara M; Moreira DR; Lalonde JM; Bewley CA; Abrams CF; Chaiken IM
    Biochemistry; 2013 Apr; 52(13):2245-61. PubMed ID: 23470147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus-Cell Interface.
    Rashad AA; Song LR; Holmes AP; Acharya K; Zhang S; Wang ZL; Gary E; Xie X; Pirrone V; Kutzler MA; Long YQ; Chaiken I
    J Med Chem; 2018 Jun; 61(11):5020-5033. PubMed ID: 29767965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120.
    Bastian AR; Kantharaju ; McFadden K; Duffy C; Rajagopal S; Contarino MR; Papazoglou E; Chaiken I
    ChemMedChem; 2011 Aug; 6(8):1335-9, 1318. PubMed ID: 21714095
    [No Abstract]   [Full Text] [Related]  

  • 15. Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.
    Aneja R; Rashad AA; Li H; Kalyana Sundaram RV; Duffy C; Bailey LD; Chaiken I
    J Med Chem; 2015 May; 58(9):3843-58. PubMed ID: 25860784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.
    Glenn MP; Pattenden LK; Reid RC; Tyssen DP; Tyndall JD; Birch CJ; Fairlie DP
    J Med Chem; 2002 Jan; 45(2):371-81. PubMed ID: 11784141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy.
    Flores A; Quesada E
    Curr Med Chem; 2013 Feb; 20(6):751-71. PubMed ID: 23278399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.
    McFadden K; Fletcher P; Rossi F; Kantharaju ; Umashankara M; Pirrone V; Rajagopal S; Gopi H; Krebs FC; Martin-Garcia J; Shattock RJ; Chaiken I
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1073-80. PubMed ID: 22083481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs.
    Tamamura H; Tsutsumi H; Masuno H; Mizokami S; Hiramatsu K; Wang Z; Trent JO; Nakashima H; Yamamoto N; Peiper SC; Fujii N
    Org Biomol Chem; 2006 Jun; 4(12):2354-7. PubMed ID: 16763678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic Characterization of Novel HIV-1 Entry Inhibitors: Discovery of a Relationship between Off-Rate and Potency.
    Meuser ME; Murphy MB; Rashad AA; Cocklin S
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30081466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.